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Abstract
Background: A polymorphic malaria parasite antigen, merozoite surface protein 3 (MSP3), is among the blood
stage malaria vaccine candidates. It is believed to induce immunity through cytophilic antibodies that disrupt the
process of erythrocytes invasion by merozoites. This study aimed at assessing natural acquisition of antibodies to
MSP3 in individuals living in an area with different malaria transmission intensity in preparation for malaria vaccine
trials.
Methods: The study was conducted in individuals aged 0-19 years from villages located in lowland, intermediate
and highland strata in Korogwe district, northeastern Tanzania. Blood samples from 492 study participants were
collected between May and June 2006 for malaria diagnosis and immunological investigations. Reactivity of MSP3
to different types of antibodies (immunoglobulin M, G and IgG subclass 1 and 3) were analysed by Enzyme Linked
ImmunoSorbent Assay (ELISA).
Results: Malaria parasite prevalence was higher in the lowland (50%) compared to the intermediate (23.1%) and
highland (9.8%) strata. Immunogloblin G subclasses 1 and 3 (IgG1 & IgG3), total IgG and IgM were found to
increase with increasing age. IgG3 levels were significantly higher than IgG1 (p < 0.001). Furthermore, Plasmodium
falciparum infection was associated with higher IgG3 levels (p = 0.008). Adjusting by strata and age in individuals
who had positive blood smears, both IgG and IgM were associated with parasite density, whereby IgG levels
decreased by 0.227 (95%CI: 0.064 - 0.391; p = 0.007) while IgM levels decreased by 0.165 (95%CI: 0.044 - 0.286;
p = 0.008).
Conclusion: Individuals with higher levels of IgG3 might be partially protected from malaria infection. Higher levels
of total IgG and IgM in highlands might be due to low exposure to malaria infection, recent infection or presence
of cross-reactive antigens. Further studies of longitudinal nature are recommended. Data obtained from this study
were used in selection of one village (Kwashemshi) for conducting MSP3 phase 1b malaria vaccine trial in
Korogwe.
Background
Malaria is one of the most serious public health pro-
blems in the world, affecting tropical developing coun-
tries and killing young children mainly [1]. Relationship
between malaria morbidity and antibody levels to
malaria antigens has been analyzed in several prospec-
tive longitudinal studies performed in different parts of
Africa and Asia [2,3]. Adults develop potent but none
sterile immunity against malaria in which individuals
chronically harbor low grade parasitaemia and only
occasionally suffer from mild clinical state known as
premunition [4,5].
Currently, a number of malaria vaccines candidates
are at different stages of clinical development. Promising
results have been obtained with some of the vaccine
candidate [6-8]. Among the blood stage candidate vac-
cines, merozoite surface protein 3 (MSP3) of Plasmo-
dium falciparum offers good prospects for a potent
vaccine whereby epidemiological and laboratory data
suggest that, immune responses targeting this antigen is
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any medium, provided the original work is properly cited.associated with protection [9]. It is believed that immu-
nity induced by MSP3 is through cytophilic antibodies
that disrupt the process of invasion of erythrocytes by
merozoites [10]. Antibodies can exert their inhibitory
function by preventing merozoite invasion into erythro-
cytes [11], by activating monocytes via cytophilic effec-
tive IgG1 and IgG3 isotypes [12] or by inhibiting
cytoadherence of infected erythrocytes. Previous studies
have demonstrated that immunoglobulin G (IgG) from
individuals who are immune to malaria could passively
transfer immunity to naïve infected recipients [11].
Immunoglobulin G cooperates with monocytes in a
mechanism of antibody-dependent cellular inhibition of
parasite growth (ADCI) in vitro [13]. Individuals pro-
tected against malaria produce mostly cytophilic antibo-
dies (IgG1 or IgG3), whereas non-protected subjects
produce mostly IgG2 and IgM [2,14]. Clinical trials of
MSP3 vaccine in healthy, semi-immune adult males in
Burkina Faso and children aged 12 to 24 months old in
Tanzania showed it was safe and immunogenic [15,16].
The aim of this study was to employ a standardized
ELISA assay to assess natural acquisition of antibodies
to MSP3 in individuals living in an area with different
malaria transmission intensity in preparation for malaria
vaccine trials.
Methods
Study area and population
This study was conducted in Korogwe district, north-
eastern Tanzania. The district is about 100 kilometers
inland from Tanga. The population of Korogwe district
in year 2002 (National census survey) was estimated to
be 261,004, with a growth rate of 1.4% per annum. The
area is topographically stratified into three strata
namely; lowland, intermediate and highland. The strata
are characterized by marked differences in malaria
transmission profiles. The altitude of Korogwe district
ranges from 300 - 1,200 meters above sea level (mASL).
In these areas, malaria transmission decreases with
increasing altitude [17,18] and is highest during and fol-
lowing the long rainy season, which usually extends
from March through July. Low transmission is experi-
enced during short rains of October - December. How-
ever, a recent study has shown non-significant
differences in malaria prevalence between the two sea-
sons [19].
In Korogwe district, the estimated average entomolo-
gical inoculation rate (EIR) ranges in the past from 30-
100 infective bites per person per year [17]. In lowland
villages of Korogwe, malaria is perennial with peak sea-
sons during and just after the rain [20]. P. falciparum is
the predominant malaria species accounting for a little
over 90% of all infections, the rest being P. malariae
and P. ovale [21]. In Korogwe District Hospital, malaria
is the leading cause of admission and deaths among
underfive children [22].
Study villages were grouped into three strata namely;
lowland, intermediate and highland based on the alti-
tude and level of transmission. Mng’aza village was cate-
gorized as lowland stratum, Kwashemshi village as
intermediate while Magundi, Kwamhanya and Vugiri vil-
lages were grouped into highland stratum. The study
involved individuals aged 0-19 years. The details of the
study villages are as explained elsewhere [19].
Study design
This study was part of a longitudinal project being con-
ducted in Korogwe. Samples used in this study were
obtained from a cross sectional malaria survey con-
ducted in May and June 2006 [19]. Plasma samples
from 492 individuals (66 lowlands, 121 intermediate and
305 highlands) were analyzed by Enzyme Linked Immu-
noSorbent Assays (ELISAs). A sample size of 89 samples
from each stratum was estimated assuming a propor-
tional mean difference of antibody levels to MSP3
between any two strata to be 30% and coefficient of var-
iation of 90%; this variation has been also shown to vary
with transmission elsewhere [23]. Thus, a minimum
sample size of 270 was required from the three strata.
For the purpose of assessing the effect of age on acquisi-
tion of antibodies, individuals were categorized into four
age-groups 0-2, 3-4, 5-9 and 10-19 years. Over sampling
was done in the highland area, because the villages were
initially earmarked for MSP3 phase 1b vaccine trial [24].
Ethical consideration
Ethical clearance was granted by the Medical Research
Co-ordinating Committee of the National Institute for
Medical Research and the Ministry of Health and Social
Welfare, Tanzania. Prior to commencement of the
study, sensitization meetings were held in each village to
explain the objectives and methodology of the study as
well as seeking for community consent. Informed con-
sent was obtained in writing from all individual partici-
pants or parents/guardians in case of children during
the survey as described elsewhere [19].
Blood sample collection
Clinical examination was done in all 492 individuals at a
central point in each village. Venous blood (about 3 ml)
from each individual was drawn into vacutainer contain-
ing EDTA anticoagulant. Out of the 3 ml of blood col-
lected, 8 μL was used for preparation of thick and thin
blood smears for malaria parasite diagnosis, species
identification and quantification. Also, 10 μL of blood of
each individual was used for estimation of haemoglobin
using Haemocue® machine. The remaining blood was
centrifuged at 2,000 revolutions per minute (rpm) to
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coat. Plasma was stored at -80°C and later analyzed for
immunological assays.
Determination of antibody responses to MSP3 by ELISA
Plasma samples were used to determine levels of IgM,
total IgG and IgG subclasses (IgG1 & IgG3) responses
to MSP3 malaria vaccine candidate by Enzyme Linked
ImmunoSorbent Assay (ELISA) technique as described
elsewhere http://www.amanet-trust.org. Briefly, wells of
the microtiter plates (Nunc, Roskilde, Denmark) were
coated with 100 μLa t0 . 5μg/ml of a recombinant pro-
tein covering the nonpolymorphic carboxy-terminal
region of the MSP3 protein (aa 212 - 380) [10]. The
antigen was supplied as a stock solution of 2.4 mg/ml
and had to be diluted so as to obtain a working concen-
tration of 0.5 μg/ml. The plates were incubated over-
night at 4°C, washed four times and blocked using (150
μL per well) 3% skimmed milk in phosphate buffered
saline (PBS) -Tween 20 (Blocking Buffer) for 1 hour.
Plasma samples (100 μL/well) at dilutions of 1:200 (for
total IgG and IgM) and 1:50 (for IgG subclasses) were
added in duplicate wells and incubated at room tem-
perature (20 - 24°C) for 2 hours. Plates for IgG1 and
IgG3 were then incubated for 1 hour with monoclonal
mouse anti-human IgG1 and IgG3 (Skybio, Wyboston
Bedfordshire, UK) as secondary antibodies at dilutions
of 1:2000, and 1:5000 respectively. The plates were
washed four times between aforementioned steps. Col-
our development was achieved either with horseradish
peroxidase-conjugated goat anti-human total IgG and
IgM (Caltag, Burlingame, CA) respectively, or horserad-
ish peroxidase-conjugated goat anti-mouse IgG (Caltag,
Burlingame, CA) for IgG subclasses followed by H2O2
with tetramethylbenzidine (TMB) substrate (Kem-En-
Tec diagnostics, Kuldyssen, DK). Absorbance was read
at 450 nm with reference at 650 nm. For each antibody
isotype, a calibration (standard) curve was obtained
from two-fold serially diluted purified myeloma proteins
coated directly to duplicate wells of the first two
columns of each plate. First well concentrations in ng/
ml were: 100 (IgG & IgG3), 500 (IgG1) and 250 (IgM).
Four pooled plasma from clinically immune adult Liber-
ians and two Danish donors never exposed to malaria
were used as positive and negative controls respectively.
Antibody units were calculated using the Afro Immuno
Assay (AIA) Network protocol of 2005 volume 1.01
excel based curve fitting program as described elsewhere
[25].
Data analysis
All data were entered and verified in Microsoft Access
while statistical analysis was done using R version 2.8.0
and STATA software version 8 (stata Corp., College sta-
tion, TX). All antibody levels were transformed to nor-
mality using the log transformation. Malaria parasite
densities were converted from parasites per 200 white
blood cells (WBCs) to parasite per microliter (μL) by
multiplying by 40. A multiple regression analysis was
used to assess variables associated with antibody levels.
A p-value < 0.05 was considered significant.
Results
Malaria infection
Table 1 gives the baseline characteristics of individuals
living in the three strata during May/June 2006 cross-
sectional survey. Out of the 492 selected individuals,
305 (62%) were from highland stratum, 121 (24.6%)
were from intermediate stratum and 66 (13.4%) were
from lowland stratum. Overall, malaria parasites preva-
lence was 20.5% (101 out of 492). Distribution of P. fal-
ciparum parasite prevalence in the three strata were
50.0% (95%CI: 37.4 - 62.6) in the lowland stratum,
23.1% (95%CI: 16.0 - 31.7) in the intermediate stratum
and 9.8% (95%CI: 6.7 - 13.7) in the highland stratum.
Intermediate stratum had low malaria parasite preva-
lence but its geometric mean parasite density (GMD)
among the positive cases was the highest among the
t h r e es t r a t a( 4 2 4r i n g s / μL; 95%CI: 187 - 964). Bednet
use was highest (91.4%) in the intermediate stratum.
Table 1 Baseline characteristics of individuals sampled from lowland, intermediate and highland strata in Korogwe,
Tanzania
Strata -Village Altitude (mASL)
(n = sample size)
P. falciparum prevalence %
(95% CI)
P. falciparum GMD
(95% CI)
δ
Splenomegaly prevalence %
(95% CI)
Bednet use
%
Lowland-Mng’aza 334 (n = 66) 50.0 (37.4,62.6) 316 (173, 578) 30.8(20.0, 43.4) 24.6
Intermediate-Kwashemshi 409 (n = 121) 23.1 (16.0,31.7) 424(187, 964) 5.8(2.4, 11.6) 91.4
Highland-Magundi 638 (n = 128) 14.1 (8.6,21.3) 237 (133,421) 10.9 (6.1,17.7) 17.19
-Kwamhanya 761(n = 86) 5.8 (1.9,13.0) 314 (63,1562) 4.7 ((1.3,11.2) 58.14
-Vugiri 941 (n = 91) 7.7 (3.1,15.2) 2020 (271,15042) 1.1(0.3,5.9) 46.15
Average(Highland) 780 (n = 305) 9.8 (6.7, 13.7) 409 (218, 765) 5.0 (2.8, 8.1) 37.4
n = number sampled, mASL = meters above sea level, GMD = Geometric mean density, % = percentage, 95%CI = 95% confidence interval,
δBased on individuals
who had positive slides only
Segeja et al. BMC Infectious Diseases 2010, 10:55
http://www.biomedcentral.com/1471-2334/10/55
Page 3 of 7Spleen rate was higher in the lowland (30.8%) compared
to the other two strata.
Immunoglobulin G1 (IgG1 subclass)
Individuals living in lowlands had higher IgG1 antibody
levels compared to negative controls while individuals
aged 10-19 years had higher mean levels than positive
control (Figure 1). Results show that levels of IgG1
adjusted for other covariates were significantly lower in
both intermediate by 1.653 (95%CI: 1.218 - 2.088; p <
0.001) and in highland strata by 1.229 (95%CI: 0.853 -
1.605; p < 0.001), when compared to the lowland stra-
tum. Increase in mean haemoglobin concentration (Hb)
by 1 g/dL was associated with decrease in IgG1 levels by
0.100 (95%CI: 0.008 - 0.192; p = 0.035). No statistically
significant association was found between IgG1 levels
and presence of P. falciparum parasites (Table 2).
Immunoglobulin G3 (IgG3 subclass)
Individuals living in lowlands had higher IgG3 antibody
levels compared to negative controls while individuals
aged 10-19 years had higher mean levels than positive
controls (Figure 1). A pattern similar to that of IgG1
antibody levels was seen for IgG3, with intermediate
and highland strata having significantly lower mean anti-
body levels compared to lowland stratum (Table 2).
The increase in IgG3 levels with age was 0.190 (95%
CI: 0.159 - 0.221; p < 0.001) and was slightly higher
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Figure 1 Distribution of geometric mean levels of IgG1, IgG3, total IgG and IgM (AU) to MSP3 by age-groups and strata. Children 0-2
years (open bars), 3-4 years (red bars) 5-9 years (green bars) and 10-19 years (blue bars) and line segments represent 95%CI. NC = Mean of
negative controls and PC = mean of positive controls for respective antibodies against MSP3.
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tion had significantly higher log mean IgG3 levels by
0.498 (95%CI: 0.131 - 0.865; p = 0.008).
Immunoglobulin G (Total IgG)
Individuals living in highlands had higher total IgG anti-
body levels compared to negative controls while indivi-
duals aged 10-19 years had higher mean levels than
positive controls (Figure 1). Mean levels of total IgG
were higher in highland stratum compared to intermedi-
ate and lowland strata (Figure 1). Levels of total IgG in
log scale as shown in table 2, were significantly lower in
the intermediate stratum by 1.168 (95%CI: 0.723 - 1.613;
p < 0.001) and higher in the highland stratum by 0.742
(95%CI: 0.358 - 1.126; p < 0.001) compared to the low-
land stratum. Individuals who had P. falciparum infec-
tion had significantly high levels of total IgG by log
2.552 (95%CI: 1.045 - 4.059, p < 0.001). Adjusting by
strata and age among individuals who had positive
blood smears, IgG levels were associated with parasite
density, whereby, the log mean levels of IgG decrease
was 0.227 (95%CI: 0.064 - 0.391; p = 0.007).
Immunoglobulin M (IgM)
Individuals living in highland stratum had higher IgM
antibody levels compared to negative controls while indivi-
duals aged 10-19 years had higher mean levels than posi-
tive control (Figure 1). Mean levels of IgM increased with
increasing altitude, the highest levels being seen in the
highland stratum (Figure 1). Log mean difference in IgM
levels in the highland stratum was 2.997 (95%CI: 2.617 -
3.377; p < 0.001) and that of intermediate stratum was
2.141 (95%CI: 1.702 - 2.580; p < 0.001) when compared to
the lowland stratum (Table 2). IgM levels were also asso-
ciated with bednet use, where in individuals who
mentioned to use bednets, log mean levels were lower by
0.338 (0.062 - 0.614; p = 0.017). Adjusting by strata and
age among individuals who had positive blood smears,
IgM levels were associated with parasite density, whereby,
the log mean levels of IgM decrease was 0.165 (95%CI:
0.044 - 0.286; p = 0.008). Individuals using bednets had
significantly (p = 0.017) lower IgM levels (Table 2).
Discussion
A number of malaria vaccine candidates are at different
stages of development and some are undergoing clinical
trials. It is believed that immunity induced by MSP3 is
through cytophilic antibodies that disrupt the process of
invasion of erythrocytes by merozoites [10]. The aim of
this study was to employ a standardized ELISA assay to
assess natural acquisition of antibodies to MSP3 in indi-
viduals living in an area with different malaria transmis-
sion intensity in preparation for malaria vaccine trials.
The burden of malaria as shown by parasite preva-
lence and spleen rate was highest in the lowland and
lowest in the highland strata as reported in other studies
[17,19,20]. High bednet use (91.4%) in the intermediate
stratum might be the main factor for the lower than
expected malaria prevalence and splenomegaly in this
stratum. Lowland rural settings are normally character-
ized by high malaria transmission intensity as shown in
our recent publication [19].
The increase in levels of total IgG, IgM, IgG1 and
IgG3 antibodies with increasing age might reflect cumu-
lative exposure to malaria parasites and possibly gradual
maturation of the immune system over time as reported
in other studies [26,27]. Both intermediate and highland
strata had significantly lower mean IgG1 levels suggest-
ing lower exposure to malaria as evidenced by the low
malaria prevalence and splenomegaly [20].
Table 2 Linear regression estimates of parameters for variables associated with antibodies to MSP3 in Korogwe,
Tanzania
Variable IgG1 IgG3 IgM IgG0
Intercept 8.363
(7.352, 9.374; p < 0.001)
5.324
(4.154,6.494; p < 0.001)
4.672
(3.651,5.693; p < 0.001)
6.906
(5.871,7.941; p < 0.001)
Intermediate stratum -1.653
(-2.088,-1.218; p < .001)
-0.917
(-1.419,-0.415; p <0.001)
2.141
(1.702,2.580; p < 0.001)
-1.168
(-1.613-0.723; p < 0.001)
Highland stratum -1.229
(-1.605,-0.853; p < 0.001)
-0.848
(-1.283,-0.413; p <0.001)
2.997
(2.617,3.377; p < 0.001)
0.742
(0.358, 1.126; p < 0.001)
Age (years) 0.120
(0.093, 0.147; p < 0.001)
0.190
(0.159,0.221; p < 0.001)
0.089
(0.062,0.116; p < 0.001)
0.084
(0.057, 0.111; p < 0.001)
Presence of
P. falciparum
0.161
(-0.155,0.477; p = 0.319)
0.498
(0.131, 0.865; p = 0.008)
0.239
(-0.080,0.558; p = 0.143)
0.101
(-0.222, 0.424; p = 0.540)
Bednet use 0.036
(-0.238,0.310; p = 0.798)
0.133
(-0.185,0.451; p = 0.411)
-0.338
(-0.614,-0.06; p = 0.017)
0.094
(-0.186, 0.374; p = 0.510)
Hb (g/dl) -0.100
(-0.192,-0.008; p = 0.035)
-0.039
(-0.147,0.069; p = 0.476)
0.031
(-0.063,0.125; p = 0.515)
0.071
(-0.023, 0.165; p = 0.140)
IgG1 = Immunoglobulin G subclass 1, IgG3 = Immunoglobulin G subclass 3, IgG0 = Total Immunoglobulin G, IgM = Immunoglobulin M, Hb = haemoglobin, < =
less than, = equal
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tum, where malaria transmission is higher, suggests fre-
quent exposure to malaria parasite as previously
reported elsewhere [28,29]. The increase of IgG3 levels
with age was slightly higher than that of IgG1 levels
which might indicate that individuals with higher levels
of IgG3 might be partially protected from malaria infec-
tion as reported in previous studies [11,30].
L o w e s tm a l a r i ap a r a s i t ep r e v a l e n c ei nh i g h l a n d si n
association with high total IgG levels, especially in those
aged 10-19 years, might indicate recent history of
malaria transmission in the highlands where malaria
infection is usually low [17,20,28] or could be due to the
presence of cross-reactive antigens. The low total IgG
levels in the intermediate stratum where bednet use was
very high (91.4%) is as reported elsewhere [31,32]. Pre-
vious studies using human sera from individuals in
malaria endemic populations have found evidence of
association between total IgG levels to MSP3 with a
reduced subsequent risk of clinical malaria [2,3].
The highest IgM levels in highland stratum in older
individuals might suggest less exposure to malaria infec-
tion. It is known that non-protected individuals produce
IgM antibodies mainly [2,14]. Furthermore, low IgM
levels seen in the lowland stratum might be due to the
continuous and intense malaria transmission. Notwith-
standing this, individuals using bednets had significantly
lower IgM levels.
Conclusion
Individuals with higher levels of IgG3 might be partially
protected from malaria infection. Higher levels of total
IgG and IgM in highlands might be due to low exposure
to malaria infection, recent infection or presence of cross-
reactive antigens. Further studies of longitudinal nature
are recommended. Data obtained from this study were
used in selection of one village (Kwashemshi) for conduct-
ing MSP3 phase 1b malaria vaccine trial in Korogwe.
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